Avadel Pharmaceuticals (AVDL) Share-based Compensation: 2009-2024
Historic Share-based Compensation for Avadel Pharmaceuticals (AVDL) over the last 16 years, with Dec 2024 value amounting to $20.4 million.
- Avadel Pharmaceuticals' Share-based Compensation fell 30.78% to $1.9 million in Q4 2022 from the same period last year, while for Dec 2022 it was $7.0 million, marking a year-over-year decrease of 20.95%. This contributed to the annual value of $20.4 million for FY2024, which is 28.94% up from last year.
- Latest data reveals that Avadel Pharmaceuticals reported Share-based Compensation of $20.4 million as of FY2024, which was up 28.94% from $15.8 million recorded in FY2023.
- In the past 5 years, Avadel Pharmaceuticals' Share-based Compensation registered a high of $20.4 million during FY2024, and its lowest value of $3.0 million during FY2020.
- In the last 3 years, Avadel Pharmaceuticals' Share-based Compensation had a median value of $15.8 million in 2023 and averaged $14.4 million.
- As far as peak fluctuations go, Avadel Pharmaceuticals' Share-based Compensation surged by 477.84% in 2020, and later declined by 20.95% in 2022.
- Avadel Pharmaceuticals' Share-based Compensation (Yearly) stood at $3.0 million in 2020, then skyrocketed by 195.83% to $8.9 million in 2021, then dropped by 20.95% to $7.0 million in 2022, then spiked by 125.45% to $15.8 million in 2023, then rose by 28.94% to $20.4 million in 2024.